Get the app
USHealthcare

Baxter International Inc (BAX)

US · Healthcare · Medical Instruments & Supplies

$23.02-2.17%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$2.96B
Revenue YoY
+5.3%
Net profit
$126.0M
Profit YoY
+38.5%
EPS
$0.56
EPS estimate
$0.36
Net margin
4.3%

EPS came in at 0.56 against a street estimate of 0.36 — a beat of 55.6%.

Key statistics

Market cap
$12.50B
Forward P/E
11.9
P/B
2.03
Book value
$12.00
EPS (TTM)
$-1.86
Dividend yield
0.82%
52-week high
$29.99
52-week low
$15.72
50-day MA
$24.82
200-day MA
$20.41
Beta
0.59

Analyst view

Analysts rate Baxter International Inc a hold (6 buy, 11 hold, 1 sell out of 18) with an average price target of $28.73.

From the latest earnings call · 2026-07-30

CONFIDENT Baxter beat Q2 expectations with 5% organic revenue growth and raised full-year guidance. Drug compounding and Advanced Surgery drove strength. $75M tariff refund aided EPS, but underlying operational performance also exceeded expectations. Q2 2026 Both U.S. and international markets showed growth; no granular breakdown provided. Dynamo stretcher launched in Canada as first international expansion. Analysts pressed on drug compounding mix impact, Novum IQ timelines, and 2027 EPS sustainability. Management downplayed single-quarter wins, emphasized GPS-driven operational cadence, and deferred 2027 guidance pending H2 execution. 2026-07-30…

Full summary in the app.

Shareholding

Insiders
0.33%
Institutions
110.24%

Largest institutional holders

FundStake
BlackRock Inc15.36%
Pzena Investment Management, LLC12.48%
Dodge & Cox11.29%
FMR Inc8.95%
Vanguard Capital Management, LLC6.48%
Vanguard Portfolio Management, LLC4.64%
State Street Corp3.86%
Greenhaven Associates Inc2.76%

Recent filings & reports

DocumentDate
Board / officer change · Q3 2026
BAXTER INTERNATIONAL INC. – 8-K SUMMARY HEADLINE NUMBERS • New CFO appointment effective October 1, 2026: John Rogers joins as Executive Vice Presid
2026-08-19
Material agreement · Q3 2026
BAXTER INTERNATIONAL INC. - FORM 8-K SUMMARY August 18, 2026 --- HEADLINE NUMBERS • Company increased aggregate purchase price cap for debt tender
2026-08-18
Board / officer change · Q3 2026
BAXTER INTERNATIONAL INC. - 8-K SUMMARY OTHER NOTABLE POINTS • Executive Departure: Interim Chief Financial Officer Anita Zielinski resigned effecti
2026-08-04
Company announcement · Q3 2026
BAXTER INTERNATIONAL INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company announced cash tender offers on August 4, 2026 to repurchase up to $500 mill
2026-08-04
Quarterly report · Q2 2026
BAXTER INTERNATIONAL INC. - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Q2 2026 Net Sales: $2,960 million (up 5.3% vs. $2,810 million in Q2 2025) • Six-
2026-07-30
Quarterly report · Q1 2026
BAXTER INTERNATIONAL INC. - Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Net sales: $2,701 million (Q1 2026) vs. $2,625 million (Q1 2025) — up 2.9% • Ope
2026-04-30
Proxy statement · Q2 2026
BAXTER INTERNATIONAL INC. — 2026 PROXY STATEMENT SUMMARY --- CEO COMPENSATION • Andrew Hider (President and CEO since August 2025) total compensati
2026-03-23
Annual report FY2025
BAXTER INTERNATIONAL INC. — 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Market capitalization: Approximately $16 billion as of June 30, 202
2026-02-12

Readable in the app.

Corporate actions

ActionDetailDate
Dividend$0.01 / share
ex-date Aug 28, 2026 · pay Oct 1, 2026
2026-08-28
Dividend$0.01 / share
ex-date May 29, 2026 · pay Jul 1, 2026
2026-05-29
Dividend$0.01 / share
ex-date Feb 27, 2026 · pay Apr 1, 2026
2026-02-27
Dividend$0.01 / share
ex-date Nov 28, 2025 · pay Jan 2, 2026
2025-11-28
Dividend$0.17 / share
ex-date Aug 29, 2025 · pay Oct 1, 2025
2025-08-29

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Baxter International Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Data updated 2026-09-18.